Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a publicly traded company as of January 2013.
Below is PrivCo's archived report for Stemline Therapeutics, Inc.

What's included with your PrivCo Report Purchase:

Next Actions on Stemline Therapeutics, Inc.:

Business Summary

Stemline Therapeutics, Inc. is a privately-held, venture capital backed clinical stage biotechnology company that engages in the acquisition, discovery, and development of novel compounds that target cancer stem cells. Founded in 2003 by Ivan Bergstein, Stemline Therapeutics, Inc. is headquartered in New York City, New York.

Jump to Stemline Therapeutics, Inc.: Detailed Business Description for more details on Stemline Therapeutics, Inc. products and services, financial structure, Stemline Therapeutics, Inc. major business events, and more.

Overview & Corporate Organization

Basic Information

Company Tags:	VC Backed
Year Founded:	2003
Fiscal Year End:	12/31
City:	New York
State/Province:	New York
Country:	United States
Phone:	View
Website:	www.stemline.com

Industry Information

Industry Codes

PICS™:	15001™, 700299™
NAICS:	View
SIC:	View

PrivCo Industries (Sector > Industry > Sub-Industry)

Technology > Biotechnology

Healthcare > Clinical Research Services > Other Clinical Research Services

The PrivCo Industry Classification System™ (PICS) is our proprietary, modernized industry classification system, geared especially toward privately-held companies and including newer emerging sub-industries that are not reflected in other outdated industry classification systems, such as SIC and NAICS.

Charts, Financials, and Statistics (Table Format)

Below are Stemline Therapeutics, Inc. financials and other business metrics displayed in table format.
Copy & Paste Financials Into Spreadsheet or

Export All Stemline Therapeutics, Inc. Financials To Excel

All data before 2006 is completely free to view! To access data from 2006 onward:

Worldwide
United States
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Washington, D.C.
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Puerto Rico
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
Canada
Alberta
British Columbia
Manitoba
New Brunswick
Newfoundland and Labrador
Northwest Territories
Nova Scotia
Nunavut
Ontario
Prince Edward Island
Quebec
Saskatchewan
Yukon
Europe (all countries)
UK
Germany
France
Italy
Europe (excluding UK)
Asia-Pacific (all countries)
Australia
China
Hong Kong
India
South Korea
Taiwan
Japan
Asia-Pacific (excluding India)
Latin America (all countries)
Middle East & Africa (all countries)

Get Full Access To This Report	or	Upgrade to PrivCo Premium
$99 Single Company Access		Instant Full Site-Wide Access *Currently 50% Off Until May. 31!*

Income Statement	2011	2010	2009	2008	2007
Revenues	View	View	View	View	View
Research And Development	View	View	View	View	View
Total Operating Expenses	View	View	View	View	View
Loss From Operations	View	View	View	View	View
Other Income	View	View	View	View	View
Other Expense	View	View	View	View	View
Interest Expense	View	View	View	View	View
Interest Income	View	View	View	View	View
Net Loss From Operations	View	View	View	View	View
Less: Accretion Of Preferred Stock Dividends	View	View	View	View	View
Add: Discount On Redemption Of Preferred Stock	View	View	View	View	View
Net (Loss) / Income Attributable To Common Stockholders	View	View	View	View	View

Balance Sheet	2011	2010	2009	2008	2007
Cash And Cash Equivalents	View	View	View	View	View
Prepaid Expenses And Other Current Assets	View	View
Total Current Assets	View	View
Deferred Financing Fees	View	View
Total Assets	View	View	View	View	View
Accrued Liabilities	View	View
Total Current Liabilities	View	View
Convertible Notes	View	View
Put Option Liability	View	View
Long-Term Liabilities	View	View	View	View	View
Total Liabilities	View	View
Total Liabilities Accrumulated During Dev. Stage	View	View	View	View	View
Preferred Stock	View	View
Common Stock	View	View
Additional Paid-In Capital	View	View
Retained Earnings/(Deficit) Accumulated During The Development Stage	View	View
Total Stockholders' Equity	View	View	View	View	View
Total Liabilities And Stockholders' Equity	View	View

Cash Flow Statement	2011	2010	2009
Net Loss	View	View	View
Stock-Based Compensation Expense	View	View	View
Non-Cash Interest Expense	View	View	View
Mark To Market Of Put Option Liability	View	View	View
Prepaid Expenses And Other Current Assets	View	View	View
Other Assets	View	View	View
Accrued Liabilities	View	View	View
Prepaid Expenses And Operating Activities	View	View	View
Purchase Of Marketable Securities	View	View	View
Redemption Of Marketable Securities	View	View	View
Net Cash Provided By Investing Activities	View	View	View
Redemption Of Preferred Stock	View	View	View
Redemption Of Preferred Common Stock	View	View	View
Proceeds From Issuance Of Convertible Notes	View	View	View
Net Cash (Used In) Provided By Financing Activities	View	View	View
Net Cash (Used In) Provided By Financing Increase In Cash And Cash Equivalents	View	View	View
Cash And Cash Equivalents At Beginning Of Period	View	View	View
Cash And Cash Equivalents At End Of Period	View	View	View

Financial Notes:
*	Stemline Therapeutics, Inc. fiscal year end: 12/31

	Date	Investor	Round	Investor Type
	Dec. 2007	View	Other	Venture Capital
	Dec. 2007	View	Other
Details		Total Round Other View
	May. 2010	View	B
Details		Total Round B View
		Total of Funding Shown Above View

	Date	Deal Type	Action	Resulting Status	Valuation	Amount Raised	Public Ticker
Details	Jan. 2013	View	View	View¹	View	View	View

1	2,275,000 shares prices...Read More →
	Full-length notes are available with Single Report Access or PrivCo Premium Subscription.

Choose Region(s):
Or Enter Location (US, CAN, UK): within miles
Annual Revenues search is available on PrivCo Premium. Upgrade to PrivCo Premium Subscription Annual Revenues:
Industry:
Go to Advanced Search

Stemline Therapeutics, Inc.

Business Summary

Overview & Corporate Organization

Basic Information

Industry Information

Industry Codes

PrivCo Industries (Sector > Industry > Sub-Industry)

Charts, Financials, and Statistics (Table Format)

Charts, Financials, and Statistics (Graphs)

Stemline Therapeutics, Inc. Research And Development ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Total Operating Expenses ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Loss From Operations ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Other Income ($): (Displayed as graph)

Stemline Therapeutics, Inc. Other Expense ($): (Displayed as graph)

Stemline Therapeutics, Inc. Interest Expense ($): (Displayed as graph)

Stemline Therapeutics, Inc. Interest Income ($): (Displayed as graph)

Stemline Therapeutics, Inc. Net Loss From Operations ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Less: Accretion Of Preferred Stock Dividends ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Add: Discount On Redemption Of Preferred Stock ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Net (Loss) / Income Attributable To Common Stockholders ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Cash And Cash Equivalents ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Prepaid Expenses And Other Current Assets ($): (Displayed as graph)

Stemline Therapeutics, Inc. Total Current Assets ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Deferred Financing Fees ($): (Displayed as graph)

Stemline Therapeutics, Inc. Total Assets ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Accrued Liabilities ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Total Current Liabilities ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Convertible Notes ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Put Option Liability ($): (Displayed as graph)

Stemline Therapeutics, Inc. Long-Term Liabilities ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Total Liabilities ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Total Liabilities Accrumulated During Dev. Stage ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Common Stock ($): (Displayed as graph)

Stemline Therapeutics, Inc. Additional Paid-In Capital ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Retained Earnings/(Deficit) Accumulated During The Development Stage ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Total Stockholders' Equity ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Total Liabilities And Stockholders' Equity ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Net Loss ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Stock-Based Compensation Expense ($): (Displayed as graph)

Stemline Therapeutics, Inc. Non-Cash Interest Expense ($): (Displayed as graph)

Stemline Therapeutics, Inc. Mark To Market Of Put Option Liability ($): (Displayed as graph)

Stemline Therapeutics, Inc. Prepaid Expenses And Other Current Assets ($): (Displayed as graph)

Stemline Therapeutics, Inc. Other Assets ($): (Displayed as graph)

Stemline Therapeutics, Inc. Accrued Liabilities ($): (Displayed as graph)

Stemline Therapeutics, Inc. Prepaid Expenses And Operating Activities ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Redemption Of Marketable Securities ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Net Cash Provided By Investing Activities ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Redemption Of Preferred Stock ($): (Displayed as graph)

Stemline Therapeutics, Inc. Redemption Of Preferred Common Stock ($): (Displayed as graph)

Stemline Therapeutics, Inc. Proceeds From Issuance Of Convertible Notes ($): (Displayed as graph)

Stemline Therapeutics, Inc. Net Cash (Used In) Provided By Financing Activities ($): (Displayed as graph)

Stemline Therapeutics, Inc. Net Cash (Used In) Provided By Financing Increase In Cash And Cash Equivalents ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Cash And Cash Equivalents At Beginning Of Period ($ MM): (Displayed as graph)

Stemline Therapeutics, Inc. Cash And Cash Equivalents At End Of Period ($ MM): (Displayed as graph)

VC/Funding Activity

Public / Private History (PPH™)

Detailed Business Description: Stemline Therapeutics, Inc.

Supplemental Resources

PrivCo Private Deals Newsletter.It's FREE!

Who We Serve

Problems We Solve

PrivCo

Stemline Therapeutics, Inc. Research And Development ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Total Operating Expenses ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Loss From Operations ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Other Income ($):
(Displayed as graph)

Stemline Therapeutics, Inc. Other Expense ($):
(Displayed as graph)

Stemline Therapeutics, Inc. Interest Expense ($):
(Displayed as graph)

Stemline Therapeutics, Inc. Interest Income ($):
(Displayed as graph)

Stemline Therapeutics, Inc. Net Loss From Operations ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Less: Accretion Of Preferred Stock Dividends ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Add: Discount On Redemption Of Preferred Stock ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Net (Loss) / Income Attributable To Common Stockholders ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Cash And Cash Equivalents ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Prepaid Expenses And Other Current Assets ($):
(Displayed as graph)

Stemline Therapeutics, Inc. Total Current Assets ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Deferred Financing Fees ($):
(Displayed as graph)

Stemline Therapeutics, Inc. Total Assets ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Accrued Liabilities ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Total Current Liabilities ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Convertible Notes ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Put Option Liability ($):
(Displayed as graph)

Stemline Therapeutics, Inc. Long-Term Liabilities ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Total Liabilities ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Total Liabilities Accrumulated During Dev. Stage ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Common Stock ($):
(Displayed as graph)

Stemline Therapeutics, Inc. Additional Paid-In Capital ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Retained Earnings/(Deficit) Accumulated During The Development Stage ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Total Stockholders' Equity ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Total Liabilities And Stockholders' Equity ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Net Loss ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Stock-Based Compensation Expense ($):
(Displayed as graph)

Stemline Therapeutics, Inc. Non-Cash Interest Expense ($):
(Displayed as graph)

Stemline Therapeutics, Inc. Mark To Market Of Put Option Liability ($):
(Displayed as graph)

Stemline Therapeutics, Inc. Prepaid Expenses And Other Current Assets ($):
(Displayed as graph)

Stemline Therapeutics, Inc. Other Assets ($):
(Displayed as graph)

Stemline Therapeutics, Inc. Accrued Liabilities ($):
(Displayed as graph)

Stemline Therapeutics, Inc. Prepaid Expenses And Operating Activities ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Redemption Of Marketable Securities ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Net Cash Provided By Investing Activities ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Redemption Of Preferred Stock ($):
(Displayed as graph)

Stemline Therapeutics, Inc. Redemption Of Preferred Common Stock ($):
(Displayed as graph)

Stemline Therapeutics, Inc. Proceeds From Issuance Of Convertible Notes ($):
(Displayed as graph)

Stemline Therapeutics, Inc. Net Cash (Used In) Provided By Financing Activities ($):
(Displayed as graph)

Stemline Therapeutics, Inc. Net Cash (Used In) Provided By Financing Increase In Cash And Cash Equivalents ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Cash And Cash Equivalents At Beginning Of Period ($ MM):
(Displayed as graph)

Stemline Therapeutics, Inc. Cash And Cash Equivalents At End Of Period ($ MM):
(Displayed as graph)

PrivCo Private Deals Newsletter.
It's FREE!